trending Market Intelligence /marketintelligence/en/news-insights/trending/gcbz60PeLZJ6bDuklKQgWw2 content esgSubNav
In This List

Dermira plans $110M common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dermira plans $110M common stock offering

Dermira Inc. plans to sell $110 million of its common shares in an underwritten public offering.

The biopharmaceutical company plans to grant the underwriters an option to buy up to an additional $16.5 million of its common stock in the offering.

Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book-runners, with Needham & Co. and H.C. Wainwright & Co. as co-managers.

Menlo Park, Calif.-based Dermira develops and commercializes therapies for patients with skin conditions. The company offers Qbrexza for the treatment of primary axillary hyperhidrosis — a certain condition in which excessive sweating occurs — in adults and pediatric patients nine years and older.